An Observational Study on The Correlation Between Time of Initiation of Avastin (Bevacizumab) Treatment And Progression-Free Survival in Patients With Metastatic Breast Cancer (CRONOS 2)

Roche

Status: Terminated

Conditions: Breast Cancer

Study type: Observational

Funder types: Industry

Identifiers

NCT01277133

ML25191

Details and patient eligibility

About

This single arm, prospective, observational study will assess the correlation between the time from start of chemotherapy to the start of Avastin (bevacizumab) treatment with progression-free survival in patients with previously untreated metastatic breast cancer. Patients will be followed for up to 12 months after progressive disease occurs.

Enrollment: 83 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult patients, >/=18 years of age
• Previously untreated metastatic breast cancer
• Scheduled to start 1st line chemotherapeutic treatment
• ECOG performance status 0-1

Exclusion criteria

• Any conditions included in contraindication list for Avastin
• Prior chemotherapy for metastatic breast cancer
• Adjuvant/neoadjuvant chemotherapy or radio-chemotherapy of non-metastatic malignancy completed <6 months prior to treatment start

Trial design

83 participants in 1 patient group

Cohort